 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ('CytoMed' or 'the Company'), a Singapore biopharmaceutical company that focuses on utilizing its licensed...

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

CytoMed Therapeutics Limited (GDTC) has released an update. CytoMed Therapeutics Limited announces a pilot program offering free cell banking to it...

CytoMed Launches Shareholder Cell Banking Program

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cytomed Therapeutics to launch complimentary cell banking

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

CytoMed diversifies into regenerative medicineSINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a Singapore-based biopharmaceutical...

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

The Company now has exclusive rights to a Malaysia, US and China patentSINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ( CytoMed or Company ), a...

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. It engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Volume (M)	3,260.00
52-Wk High	$9.25
52-Wk Low	$1.92

GDTC CYTOMED THERAPEUTICS LIMITED

About

Feed

News

Fundamentals